Oct 8, 2025 7:30 am EDT Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy
Oct 1, 2025 7:30 am EDT Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 2, 2025 7:30 am EDT Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 29, 2025 7:30 am EDT Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
Aug 14, 2025 7:30 am EDT Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
Aug 1, 2025 7:30 am EDT Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 15, 2025 7:30 am EDT ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
Jul 2, 2025 7:30 am EDT Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
Jul 1, 2025 7:30 am EDT Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
Jul 1, 2025 7:15 am EDT Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
